Latest Industry Insights

Flow cytometry is a technique used to count and analyze the size, shape and properties of individual cells. Not just a valuable research tool, flow cytometry is also finding its stride in several clinical areas. Following BD Biosciences’ launch of a new sample preparation instrument, we spoke to Stephen Gunstream, VP and general manager, to get his insights on the role of flow cytometry in the clinic.

We recently spoke to Charlie Silver, CEO and Co-Founder of Mission Bio, to learn more about how they are helping researchers profile mutational heterogeneity at the single-cell level.

DNAfit is a personalized health and wellness company that offers an array of nutritional profiling services based on genetic science and technology. We spoke with Avi Lasarow, CEO and founder of DNAFit, to learn more about why it is important to look at our genetics in relation to diet and exercise choices, and what research currently exists in the field.

In the development of a therapeutic pharmaceutical agent, it is crucial to understand the on- and off-target effects the molecule may have within the body. Cyclica's Ligand Express® is a cloud-based platform that screens small-molecule drugs against structurally-characterized proteins, or "proteomes" to determine polypharmacological profiles. We spoke with Naheed Kurji, President & CEO, and Andreas Windemuth, Chief Science Officer, from Cyclica to find out more.

This year’s Advances in Genome Biology and Technology meeting showcased some of the most exciting developments in genomic technology. We caught up with Twist Bioscience CEO Emily Leproust to discuss the importance of target enrichment in next generation sequencing and the advancements in the field that caught her eye at AGBT.

Despite the great excitement about exosomes and their huge diagnostic and therapeutic potential, the technology needed to advance this work is lacking. We spoke to Jim West, CEO of Clara Biotech, who tells us how his team is working to fill that gap.

Major advances have occurred in the fields of proteomics and genomics over recent years. Now, scientists are utilizing the technologies from each approach collectively in a novel research area named proteogenomics. We spoke with Alexzander Asea, Professor and Director at Precision Therapeutics Proteogenomics Diagnostics Center, University of Toledo, to learn more about the applications of proteogenomics in precision medicine.

Researchers have developed a mathematical model that may offer an alternative to relying on ultrasound information for calculating gestational age. The model, utilizing a "metabolomic fingerprint" approach, may overcome barriers in preterm death research.

The European Proteomics Infrastructure Consortium providing access (EPIC-XS) consists of a network of experienced research groups that share one common goal: to facilitate the development and sustainability of proteomics explorations to researchers within the European Union. We spoke with Martina O’Flaherty from the EPIC-XS project office to learn more.

Last year the smallest CRISPR protein, Cas14 was discovered. We spoke to the scientists that made the discovery, Lucas Harrington, at Mammoth Biosciences, to learn more about Cas14.